Cyclodextrin-Based Delivery Systems for Anticancer Drugs, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 315

Special Issue Editors


E-Mail Website
Guest Editor
1. Departament of Pharmaceutical Chemistry, Faculty of Pharmacy, Victor Babeş University of Medicine and Pharmacy Timisoara, 2nd EftimieMurgu Sq., 300041 Timişoara, Romania
2. Research Center for Pharmaco-Toxicological Evaluations, Faculty of Pharmacy, Victor Babes University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania
Interests: supramolecular compounds; anticancer therapy; targeted therapy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Department of Toxicology and Drug Industry, Faculty of Pharmacy, Victor Babeş University of Medicine and Pharmacy Timişoara, 2 Eftimie Murgu Street, 300041 Timişoara, Romania
2. Research Center for Pharmaco-Toxicological Evaluations, Faculty of Pharmacy, Victor Babes University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Square, 300041 Timisoara, Romania
Interests: toxicology; nanoparticles; natural and synthetic drugs; natural compounds; derivatization
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Analytical Chemistry , Faculty of Pharmacy, “Victor Babeş” University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania
Interests: stability of drugs and compounds with potential biological activity; instrumental analysis of drugs as pure APIs and in pharmaceutical dosage forms
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Malignant diseases are one of the most powerful diseases of the current century, representing a major cause of death at a global level. Even though anticancer research and drug discovery continuously increase the therapeutic options, chemotherapy remains a method with many drawbacks due to poor bioavailability, side effects, drug resistance, and target specificity.

In addition to the screening of synthetic molecules with anticancer potential, natural compounds represent a valuable alternative to the limitations of conventional chemotherapy. Natural compounds also face drawbacks that limit their utilization, such as poor water solubility, low dissolution rate, bioavailability, and increased sensitivity to degradation and inactivation. 

Today, cyclodextrins are considered valuable pharmaceutical excipients due to their ability to partly or completely include a drug molecule, thus improving the unfavorable physicochemical and the biological properties of the hosted molecule. Moreover, the protection and, especially, the controlled release of various organic compounds are carried out almost exclusively via encapsulation.

Currently, the development of improved formulations based on natural and synthetic compounds with increased bioavailability and stability, along with dose reduction and the reduction in adverse effects, represents a topical issue to be explored.

This Special Issue will bring together recent data regarding the role of cyclodextrins in developing improved delivery systems containing anticancer compounds. We welcome reviews and original research on all aspects of the influence of cyclodextrin complexation on the physicochemical and biological properties of anticancer drugs.

Dr. Cristina Trandafirescu
Dr. Iulia Pinzaru
Dr. Denisa Laura Cîrcioban
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cyclodextrins
  • delivery systems
  • anticancer compounds
  • natural compounds
  • bioavailability
  • stability

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop